2025
SJR Q1
JCR Q2 · 2,6
29 matched articles
SCIE
Journal detail
Pharmacoepidemiology and Drug Safety
- Publisher
- John Wiley and Sons Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
1053856910991557
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,041
- Quartile Q1
- H-Index 117
- Cites/doc 2,39
- Docs (3y) 537
- Cites (3y) 1.332
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,6
- 5Y JIF 2,9
- JCI 0,64
WoS indexes
- SCIE
Subject classification
Categories (SJR)
Areas
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 1,041 | 2,6 | 2,9 | 0,64 | Q2 | 117 |
| 2024 | Q1 | Q2 | 1,022 | 2,4 | 2,5 | 0,62 | Q3 | 113 |
| 2023 | Q1 | Q2 | 1,106 | 2,4 | 2,6 | 0,62 | Q3 | 113 |
| 2022 | Q1 | Q3 | 1,067 | 2,6 | 3 | 0,62 | Q3 | 113 |
| 2021 | Q2 | Q3 | 0,868 | 2,7 | 3,1 | 0,68 | Q2 | 113 |
| 2020 | Q2 | Q2 | 1,023 | 2,9 | 3,3 | 0,95 | Q2 | 113 |
| 2019 | Q1 | Q2 | 1,223 | 2,9 | 2,8 | 1,03 | Q1 | 113 |
| 2018 | — | Q1 | — | 2,9 | 3 | 1,06 | Q1 | — |
| 2017 | Q1 | Q2 | 1,329 | 2,3 | 2,8 | 0,98 | Q2 | 113 |
| 2016 | Q1 | Q2 | 1,513 | 2,6 | 3,1 | — | — | 113 |
| 2015 | Q1 | Q2 | 1,908 | 2,9 | 3,1 | — | — | 113 |
| 2014 | Q1 | Q2 | 1,929 | 2,9 | 3,1 | — | — | 113 |
| 2013 | Q1 | Q2 | 1,651 | 3,2 | 3 | — | — | 113 |
| 2012 | Q1 | Q2 | 1,725 | 2,9 | 2,9 | — | — | 113 |
| 2011 | Q1 | Q2 | 1,382 | 2,5 | 2,7 | — | — | 113 |
| 2010 | Q1 | Q3 | 1,534 | 2,3 | 2,7 | — | — | 113 |
| 2009 | — | Q2 | — | 2,5 | 2,7 | — | — | — |
| 2008 | — | Q2 | — | 2,5 | 2,6 | — | — | — |
| 2007 | — | Q2 | — | 2,5 | 2,4 | — | — | — |
| 2006 | — | Q2 | — | 2,2 | — | — | — | — |
| 2005 | — | Q3 | — | 1,8 | — | — | — | — |
| 2004 | — | Q2 | — | 2,1 | — | — | — | — |
| 2003 | — | Q3 | — | 1,3 | — | — | — | — |
| 2002 | — | Q3 | — | 1,1 | — | — | — | — |
| 2001 | — | Q3 | — | 1,3 | — | — | — | — |
| 2000 | — | Q3 | — | 0,9 | — | — | — | — |
| 1999 | — | Q3 | — | 0,8 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 195/356 |
| 2025 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q2 | Q3 | 173/443 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 195/352 |
| 2024 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q2 | Q3 | 158/421 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 188/354 |
| 2023 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q2 | Q3 | 165/408 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 183/278 |
| 2022 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q3 | Q3 | 128/207 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 192/279 |
| 2021 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q3 | Q2 | 133/210 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 171/276 |
| 2020 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q2 | Q2 | 93/203 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 118/271 |
| 2019 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q2 | Q1 | 54/193 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 113/267 |
| 2018 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q1 | Q1 | 46/186 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 145/261 |
| 2017 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q2 | Q2 | 66/181 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 121/257 |
| 2016 | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SCIE | Q2 | — | 47/176 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 82/255 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 86/255 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 66/256 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 81/261 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 106/261 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 127/252 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 105/237 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 94/219 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 77/205 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 95/199 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 104/193 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 72/187 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 120/185 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 122/188 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 99/186 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 130/181 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 114/175 |